Valerie M Vaughn1,2, Sarah M Seelye1, Xiao Qing Wang1,3, Wyndy L Wiitala1, Michael A Rubin4,5, Hallie C Prescott1,3. 1. Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA. 2. Division of Hospital Medicine, Department of Internal Medicine, Michigan Medicine, Ann Arbor, Michigan, USA. 3. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Michigan Medicine, Ann Arbor, Michigan, USA. 4. VA Salt Lake City Health Care System, Salt Lake City, Utah, USA. 5. University of Utah School of Medicine, Salt Lake City, Utah, USA.
Abstract
BACKGROUND: Between 2007 and 2015, inpatient fluoroquinolone use declined in US Veterans Affairs (VA) hospitals. Whether fluoroquinolone use at discharge also declined, in particular since antibiotic stewardship programs became mandated at VA hospitals in 2014, is unknown. METHODS: In this retrospective cohort study of hospitalizations with infection between January 1, 2014, and December 31, 2017, at 125 VA hospitals, we assessed inpatient and discharge fluoroquinolone (ciprofloxacin, levofloxacin, moxifloxacin) use as (a) proportion of hospitalizations with a fluoroquinolone prescribed and (b) fluoroquinolone-days per 1000 hospitalizations. After adjusting for illness severity, comorbidities, and age, we used multilevel logit and negative binomial models to assess for hospital-level variation and longitudinal prescribing trends. RESULTS: Of 560219 hospitalizations meeting inclusion criteria as hospitalizations with infection, 37.4% (209602/560219) had a fluoroquinolone prescribed either during hospitalization (32.5%, 182337/560219) or at discharge (19.6%, 110003/560219). Hospitals varied appreciably in inpatient, discharge, and total fluoroquinolone use, with 71% of hospitals in the highest prescribing quartile located in the Southern United States. Nearly all measures of fluoroquinolone use decreased between 2014 and 2017, with the largest decreases found in inpatient fluoroquinolone and ciprofloxacin use. In contrast, there was minimal decline in fluoroquinolone use at discharge, which accounted for a growing percentage of hospitalization-related fluoroquinolone-days (52.0% in 2014; 61.3% by 2017). CONCLUSIONS: Between 2014 and 2017, fluoroquinolone use decreased in VA hospitals, largely driven by decreased inpatient fluoroquinolone (especially ciprofloxacin) use. Fluoroquinolone prescribing at discharge, as well as levofloxacin prescribing overall, is a growing target for stewardship. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2020.
BACKGROUND: Between 2007 and 2015, inpatient fluoroquinolone use declined in US Veterans Affairs (VA) hospitals. Whether fluoroquinolone use at discharge also declined, in particular since antibiotic stewardship programs became mandated at VA hospitals in 2014, is unknown. METHODS: In this retrospective cohort study of hospitalizations with infection between January 1, 2014, and December 31, 2017, at 125 VA hospitals, we assessed inpatient and discharge fluoroquinolone (ciprofloxacin, levofloxacin, moxifloxacin) use as (a) proportion of hospitalizations with a fluoroquinolone prescribed and (b) fluoroquinolone-days per 1000 hospitalizations. After adjusting for illness severity, comorbidities, and age, we used multilevel logit and negative binomial models to assess for hospital-level variation and longitudinal prescribing trends. RESULTS: Of 560219 hospitalizations meeting inclusion criteria as hospitalizations with infection, 37.4% (209602/560219) had a fluoroquinolone prescribed either during hospitalization (32.5%, 182337/560219) or at discharge (19.6%, 110003/560219). Hospitals varied appreciably in inpatient, discharge, and total fluoroquinolone use, with 71% of hospitals in the highest prescribing quartile located in the Southern United States. Nearly all measures of fluoroquinolone use decreased between 2014 and 2017, with the largest decreases found in inpatient fluoroquinolone and ciprofloxacin use. In contrast, there was minimal decline in fluoroquinolone use at discharge, which accounted for a growing percentage of hospitalization-related fluoroquinolone-days (52.0% in 2014; 61.3% by 2017). CONCLUSIONS: Between 2014 and 2017, fluoroquinolone use decreased in VA hospitals, largely driven by decreased inpatient fluoroquinolone (especially ciprofloxacin) use. Fluoroquinolone prescribing at discharge, as well as levofloxacin prescribing overall, is a growing target for stewardship. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2020.
Entities:
Keywords:
antibiotic stewardship; fluoroquinolones; infection; transitions of care; veterans
Authors: Allison A Kelly; Makoto M Jones; Kelly L Echevarria; Stephen M Kralovic; Matthew H Samore; Matthew B Goetz; Karl J Madaras-Kelly; Loretta A Simbartl; Anthony P Morreale; Melinda M Neuhauser; Gary A Roselle Journal: Infect Control Hosp Epidemiol Date: 2017-01-25 Impact factor: 3.254
Authors: Kirstin Manges; Patricia S Groves; Amany Farag; Ryan Peterson; Joanna Harton; S Ryan Greysen Journal: BMJ Qual Saf Date: 2019-11-27 Impact factor: 7.035
Authors: Juan Merlo; Basile Chaix; Henrik Ohlsson; Anders Beckman; Kristina Johnell; Per Hjerpe; L Råstam; K Larsen Journal: J Epidemiol Community Health Date: 2006-04 Impact factor: 3.710
Authors: Valerie M Vaughn; Tejal Gandhi; Anna Conlon; Vineet Chopra; Anurag N Malani; Scott A Flanders Journal: Clin Infect Dis Date: 2019-09-27 Impact factor: 9.079
Authors: Scott Fridkin; James Baggs; Ryan Fagan; Shelley Magill; Lori A Pollack; Paul Malpiedi; Rachel Slayton; Karim Khader; Michael A Rubin; Makoto Jones; Matthew H Samore; Ghinwa Dumyati; Elizabeth Dodds-Ashley; James Meek; Kimberly Yousey-Hindes; John Jernigan; Nadine Shehab; Rosa Herrera; Clifford L McDonald; Amy Schneider; Arjun Srinivasan Journal: MMWR Morb Mortal Wkly Rep Date: 2014-03-07 Impact factor: 17.586
Authors: Federico Perez; Roberto Viau Colindres; Brigid M Wilson; Elie Saade; Robin L P Jump; Ritu Banerjee; Robin Patel; Scott R Evans; Robert A Bonomo Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 9.079
Authors: Valerie M Vaughn; Tejal N Gandhi; Vineet Chopra; Lindsay A Petty; Daniel L Giesler; Anurag N Malani; Steven J Bernstein; Lama M Hsaiky; Jason M Pogue; Lisa Dumkow; David Ratz; Elizabeth S McLaughlin; Scott A Flanders Journal: Clin Infect Dis Date: 2021-12-06 Impact factor: 9.079
Authors: Nicholas J Mercuro; Corey J Medler; Rachel M Kenney; Nancy C MacDonald; Melinda M Neuhauser; Lauri A Hicks; Arjun Srinivasan; George Divine; Amy Beaulac; Erin Eriksson; Ronald Kendall; Marilen Martinez; Allison Weinmann; Marcus Zervos; Susan L Davis Journal: JAMA Netw Open Date: 2022-05-02
Authors: Valerie M Vaughn; Tejal N Gandhi; Timothy P Hofer; Lindsay A Petty; Anurag N Malani; Danielle Osterholzer; Lisa E Dumkow; David Ratz; Jennifer K Horowitz; Elizabeth S McLaughlin; Tawny Czilok; Scott A Flanders Journal: Clin Infect Dis Date: 2022-08-31 Impact factor: 20.999